Levosimendan Improves Hemodynamics And Submaximal Exercise Capacity In Ph-hfpef: Primary Results From The Help-ph-hfpef Multicenter Randomized Controlled Trial

There is currently no effective treatment for patients with HFpEF and pulmonary hypertension (PH-HFpEF). We hypothesized that levosimendan (LEVO), a calcium sensitizer with inotropic and vascular smooth muscle relaxant properties, would improve hemodynamics and exercise capacity in PH-HFpEF.

Source: Journal of Cardiac Failure - December 1, 2020 Category: Cardiology Authors: Barry A. Borlaug, Daniel Burkhoff, Sanjiv Shah, Ronald Zolty, Ryan Tedford, Thenappan Thenappan, Roham Zamanian, Jeremy Mazurek, Jonathan Rich, Marc Simon, Stuart Rich Source Type: research